Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 13/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025273 | 0.85 | ITGB3 (0.45) | — | |
| Trifluoroacetic Acid SCHEMBL1026518 | 0.83 | FFAR4 (0.49) | CHRM4FFAR4 | |
| SCHEMBL13622700 | 0.81 | FFAR4 (0.48) | CHRM4FFAR4 | |
| SCHEMBL1024922 | 0.80 | CHRM2 (0.46) | CHRM4FFAR4 | |
| SCHEMBL4365334 | 0.79 | CHRM4 (0.48) | CHRM4FFAR4 | |
| SCHEMBL1026507 | 0.79 | KDM4E (0.47) | CHRM4 | |
| SCHEMBL1026519 | 0.78 | MAPT (0.40) | CHRM4ACACB | |
| SCHEMBL1024330 | 0.77 | ALDH1A1 (0.52) | USP30 | |
| SCHEMBL4352889 | 0.77 | FAAH (0.37) | FFAR4 | |
| SCHEMBL4364569 | 0.77 | LSS (0.43) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CHRM4 4834/4885FFAR4 2075/4885DEGS1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.